Traditionally, experimental mutagenesis studies have been limited to the analysis of mutations in a single gene (e.g., HPRT, lacZ, cII, TP53) which were identified in tumours or by specifically selecting for the growth of mutated cells or clones from mutagen-treated cell populations. The gene discussed is TP53; the disease is neoplasm.